Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Community Doc's View: Discussing new data and products in Renal Cell Carcinoma, including Exelixis' Cabozantinib with a Medical Oncologist in Private Practice

Ticker(s): EXEL, MRK

Who's the expert?

Name: Dr Abhimanyu Ghose - MD

Institution: Arizona Oncology

  • Medical Oncologist who is board certified in internal medicine and medical oncology and hematology in multi-speciality private practice including urology and oncology.
  • Actively manages 75 patients (total) with breast cancer, and 10-15 patients with RCC a month.
  • Has more than 20 peer-reviewed articles in the field of oncology and has presented in national and international conferences including ACP, ASCO, SGIM and ASH; specializes in treating patients with all types of cancer including lung, gastrointestinal, breast, genitourinary (bladder, prostate, renal), skin, myeloma, lymphomas and other blood disorders.

Interview Goal
To get a better understanding of the renal cell carcinoma landscape and clinical use of Cabozantinib.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.